FDA
-
-
-
-
-
-
-
BioCryst receives FDA approval for ORLADEYO oral pellets for children
-
-
-
-
-
-
-
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
-
-
-
-
-
-
-
BioCryst names Charlie Gayer as next CEO after Jon Stonehouse retires
-
-
-
-
-
-
-
BioCryst Pharma (BCRX): ORLADEYO Approved in Colombia
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

